Catalyst
Slingshot members are tracking this event:
Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PTLA | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 01, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Cerdulatinib, Phase 2a Study, Eha Annual Meetings, Asco
